| Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients (NCT00893035) | Institut du Cancer de Montpellier - Val d'Aurelle | 2006-06-01 |
| MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer (NCT00374049) | Olivera Finn | 2006-06-01 |
| Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy (NCT00790595) | Jonsson Comprehensive Cancer Center | 2006-06-01 |
| Study of Quality of Life for Prostate Proton Therapy (NCT00489814) | M.D. Anderson Cancer Center | 2006-05-24 |
| DNA Changes in Patients With Prostate Cancer (NCT00899184) | ECOG-ACRIN Cancer Research Group | 2006-05-23 |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (NCT00329043) | M.D. Anderson Cancer Center | 2006-05-15 |
| Quality of Life in Men With High Risk Localized Prostate Cancer (NCT00877617) | M.D. Anderson Cancer Center | 2006-05-01 |
| Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer (NCT00514540) | M.D. Anderson Cancer Center | 2006-05-01 |
| Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer (NCT00348816) | The University of Texas Health Science Center at San Antonio | 2006-05-01 |
| Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. (NCT00258765) | Novartis Pharmaceuticals | 2006-05-01 |
| A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer (NCT00326586) | Bristol-Myers Squibb | 2006-05-01 |
| Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer (NCT00334139) | Novartis Pharmaceuticals | 2006-05-01 |
| BAY88-8223, Dose Finding Study in Patients With HRPC (NCT00337155) | Bayer | 2006-05-01 |
| PROFIT - Prostate Fractionated Irradiation Trial (NCT00304759) | Ontario Clinical Oncology Group (OCOG) | 2006-05-01 |
| Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer (NCT00372840) | Fox Chase Cancer Center | 2006-05-01 |
| Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo (NCT00332280) | Auron Healthcare GmbH | 2006-05-01 |
| Internet Support for Cancer Patients (NCT00710658) | Oslo University Hospital | 2006-05-01 |
| Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds (NCT00348465) | New York Presbyterian Brooklyn Methodist Hospital | 2006-05-01 |
| Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy (NCT00312442) | STEBA France | 2006-05-01 |
| High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer (NCT00561262) | University College London Hospitals | 2006-05-01 |
| The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer (NCT00605488) | Memorial Sloan Kettering Cancer Center | 2006-04-25 |
| Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer (NCT00321698) | OHSU Knight Cancer Institute | 2006-04-21 |
| Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer (NCT00349557) | Benaroya Research Institute | 2006-04-01 |
| Patient Preference Survey for Radiation Oncologists (NCT00595218) | University of Pittsburgh | 2006-04-01 |
| Radiation Therapy in Treating Patients With Stage II Prostate Cancer (NCT00331773) | Radiation Therapy Oncology Group | 2006-04-01 |
| Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer (NCT00295802) | EDAP TMS S.A. | 2006-04-01 |
| Vidaza to Restore Hormone Thx Prostate (NCT00384839) | US Oncology Research | 2006-04-01 |
| Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer (NCT00616291) | Baylor College of Medicine | 2006-04-01 |
| Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer (NCT00348998) | Virginia Mason Hospital/Medical Center | 2006-04-01 |
| Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00524589) | Roswell Park Cancer Institute | 2006-04-01 |
| Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU) (NCT00318240) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2006-04-01 |
| Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer (NCT00303914) | Eastern Cooperative Oncology Group | 2006-03-14 |
| CyberKnife Radiosurgery for Localized Prostatic Carcinoma (NCT01045148) | CyberKnife Centers of San Diego | 2006-03-01 |
| Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04 (NCT00949338) | Cancer Trials Ireland | 2006-03-01 |
| A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel (NCT00313456) | Agennix | 2006-03-01 |
| PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer (NCT00379561) | Sophiris Bio Corp | 2006-03-01 |
| Prostate Adenocarcinoma TransCutaneous Hormones (NCT00303784) | University College, London | 2006-03-01 |
| Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy (NCT00511498) | Johns Hopkins University | 2006-03-01 |
| Study of SU11248 in Men With Advanced Prostate Cancer (NCT00299741) | Massachusetts General Hospital | 2006-03-01 |
| Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure (NCT00305929) | STEBA France | 2006-03-01 |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer (NCT00601406) | The Christie NHS Foundation Trust | 2006-03-01 |
| Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors (NCT00335491) | University of Utah | 2006-03-01 |
| Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) (NCT00307294) | University of Pittsburgh | 2006-03-01 |
| A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD (NCT00378690) | Astellas Pharma Inc | 2006-03-01 |
| Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC (NCT00314782) | AstraZeneca | 2006-03-01 |
| Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy (NCT00329797) | Radiation Therapy Oncology Group | 2006-03-01 |
| Active Surveillance in Prostate Cancer (NCT00490763) | M.D. Anderson Cancer Center | 2006-02-13 |
| Lycopene in Preventing Prostate Cancer in Healthy Participants (NCT00322114) | University of Illinois at Chicago | 2006-02-01 |
| Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15 (NCT00955435) | Cancer Trials Ireland | 2006-02-01 |
| An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 (NCT00818480) | Astellas Pharma Inc | 2006-02-01 |
| Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy (NCT00373035) | Wake Forest University Health Sciences | 2006-02-01 |
| Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC (NCT00286793) | Ascenta Therapeutics | 2006-02-01 |
| Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (NCT00313599) | University of California, San Francisco | 2006-02-01 |
| Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer (NCT00391690) | Novartis | 2006-02-01 |
| The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer (NCT00295750) | Ferring Pharmaceuticals | 2006-02-01 |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer (NCT00338026) | Thallion Pharmaceuticals | 2006-02-01 |
| Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00323882) | Bristol-Myers Squibb | 2006-01-01 |
| Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer (NCT00288444) | Emory University | 2006-01-01 |
| GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere (NCT00274287) | Oncology Specialists, S.C. | 2006-01-01 |
| DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) (NCT00273338) | Novacea | 2006-01-01 |
| ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer (NCT00544076) | City of Hope Medical Center | 2006-01-01 |
| Acupuncture Treatment for Hot Flashes Study (NCT00421902) | New York Presbyterian Brooklyn Methodist Hospital | 2006-01-01 |
| Metronomic Oral Vinorelbine in Patients With Metastatic Tumors (NCT00278070) | Hellenic Cooperative Oncology Group | 2006-01-01 |
| Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib (NCT00203424) | Translational Oncology Research International | 2006-01-01 |
| Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer (NCT00268892) | Ferring Pharmaceuticals | 2006-01-01 |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy (NCT00278993) | Eisai Inc. | 2006-01-01 |
| Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer (NCT00897793) | Vanderbilt-Ingram Cancer Center | 2006-01-01 |
| Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer (NCT00242567) | Novartis Pharmaceuticals | 2005-12-01 |
| Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer (NCT00272038) | Oncology Specialists, S.C. | 2005-12-01 |
| Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone (NCT00392938) | University of Washington | 2005-12-01 |
| Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer (NCT00288080) | Radiation Therapy Oncology Group | 2005-12-01 |
| Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation (NCT00264420) | The Cleveland Clinic | 2005-12-01 |
| E3-Hormone Refractory Prostrate Cancer Taxotere Combination (NCT00498797) | Sanofi | 2005-12-01 |
| Effects of ASA on Prostate Tissue (NCT00234299) | University of Washington | 2005-12-01 |
| Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer (NCT00244309) | Case Comprehensive Cancer Center | 2005-11-01 |
| The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer (NCT00459186) | Dana-Farber Cancer Institute | 2005-11-01 |
| Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer (NCT00336934) | Roll International Corporation | 2005-11-01 |
| Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients. (NCT00554086) | Canadian Urology Research Consortium | 2005-11-01 |
| Identification of Risk Allels for Prostate Cancer (NCT00323388) | University of New Mexico | 2005-11-01 |
| Shared Decision Making: Prostate Cancer Screening (NCT00207649) | Lisa Richarson | 2005-11-01 |
| Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma (NCT00252941) | The Cleveland Clinic | 2005-11-01 |
| FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer (NCT00282906) | University of Southern California | 2005-10-03 |
| Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)" (NCT02167893) | Takeda | 2005-10-01 |
| Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer (NCT00176293) | University of Kentucky | 2005-10-01 |
| Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer (NCT00376792) | Scandinavian Prostate Cancer Group | 2005-10-01 |
| AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma (NCT00562380) | Amgen | 2005-10-01 |
| Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients (NCT00327288) | AmpliMed Corporation | 2005-10-01 |
| Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer? (NCT00215631) | Erasmus Medical Center | 2005-10-01 |
| Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer (NCT00276549) | Case Comprehensive Cancer Center | 2005-10-01 |
| Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions (NCT00250757) | New Mexico Cancer Research Alliance | 2005-10-01 |
| MRI/MRSI in Risk Assessment of Prostate Cancer Patients (NCT00582543) | Memorial Sloan Kettering Cancer Center | 2005-10-01 |
| Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00246753) | UNC Lineberger Comprehensive Cancer Center | 2005-10-01 |
| Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (NCT00258388) | NCIC Clinical Trials Group | 2005-09-28 |
| Intensity Modulated Radiation Therapy for Prostate Cancer (NCT00214422) | National Cancer Institute (NCI) | 2005-09-19 |
| Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy (NCT00499421) | M.D. Anderson Cancer Center | 2005-09-14 |
| S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT (NCT00288106) | SWOG Cancer Research Network | 2005-09-01 |
| Fulvestrant in Treating Patients With Advanced Prostate Cancer (NCT00244998) | Roswell Park Cancer Institute | 2005-09-01 |
| Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma (NCT00400894) | ProteoSys AG | 2005-09-01 |
| Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (NCT01172028) | University of Arizona | 2005-09-01 |
| Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer (NCT00128531) | GP-Pharm | 2005-09-01 |